Clinical and Genetic Overview of Neurofibromatosis Type 2 (NF2)
- Author:
Tae-Kyun KIM
1
;
Young-Soo PARK
;
Ichiro NAKAGAWA
Author Information
- Publication Type:Review Article
- From:Journal of Korean Neurosurgical Society 2025;68(3):272-277
- CountryRepublic of Korea
- Language:English
- Abstract: Neurofibromatosis type 2 (NF2) is an autosomal dominant disease characterized by bilateral vestibular schwannomas and other central nervous tumors such as meningiomas and spinal ependymomas. Symptoms vary according to the age at diagnosis and the location of these tumors. The diagnostic criteria of NF2 have been regularly revised and recently updated in 2022 with a new nomenclature “NF2-related schwannomatosis” to differentiate NF2 from other schwannoma predisposing disorders, such as SMARCB1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1)-, LZTR1 (leucine zipper-like transcription regulator 1)-, and 22q-related schwannomatosis. Addition to the clinical features, genetic testing for pathogenic variants in these genes became an important essence to support diagnosis of NF2 and other schwannomatosis, including mosaic conditions.
